FAIM
SEEL

Financial Advocates Investment Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Financial Advocates Investment Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6
Closed -$1.99M – 833
2021
Q4 		$1.99M Buy
+6
New +$46.1K 0.13% 198

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Financial Advocates Investment Management's SEEL Position: Q1 2022 in Review

Financial Advocates Investment Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022, closing a stake of 6 shares — an estimated $1.99M sold.

Financial Advocates Investment Management first reported a position in SEEL in Q4 2021 and held it in 1 quarter. The position peaked at $1.99M in Q4 2021. 77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

  • Financial Advocates Investment Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 6 Seelos Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.99M.
  • Financial Advocates Investment Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Financial Advocates Investment Management's Seelos Therapeutics, Inc. Common Stock position peaked at $1.99M in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Financial Advocates Investment Management's 13F filing for Q1 2022, filed 11 May 2022.